文献速递肿瘤 PET/CT

18F-PSMA-1007与18F-氟胆碱PET/CT在生化复发前列腺癌中的头对头比较

Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该前瞻性研究纳入40例根治性治疗后生化复发且PSA≤2.0 ng/mL的前列腺癌患者,在平均间隔54±21天内分别行18F-FCH和18F-PSMA-1007 PET/CT。结果显示18F-PSMA-1007阳性率更高(60% vs 5%),检出病灶数更多(184 vs 63,P=0.0006),高度可疑病灶比例更高。

要点

  • 18F-PSMA-1007在低PSA生化复发患者中阳性率显著高于18F-FCH(60% vs 5%)。
  • 18F-PSMA-1007检出病灶总数更多(184 vs 63,P=0.0006),高度可疑病灶占74%。
  • 18F-PSMA-1007高度可疑病灶SUVmax显著高于不确定病灶(中位3.6 vs 2.5,P<0.00001)。

核心结论

  • 在早期生化复发前列腺癌患者中,18F-PSMA-1007 PET/CT的检出率高于18F-FCH PET/CT。
  • 18F-PSMA-1007检出病灶总数更多、高度可疑病灶更多、不确定病灶更少。

研究设计与样本

  • 前瞻性纳入40例根治性治疗后生化复发且PSA≤2.0 ng/mL的前列腺癌患者。
  • 患者先后接受18F-FCH和18F-PSMA-1007 PET/CT,平均间隔54±21天。
  • 18F-FCH注射剂量248±35 MBq,注射后87±10分钟扫描;18F-PSMA-1007注射剂量295±14 MBq,注射后95±12分钟扫描。

主要发现

  • 18F-PSMA-1007阳性、不确定、阴性结果分别占60%、27.5%、12.5%;18F-FCH分别占5%、37.5%、57.5%。
  • 70%的扫描中18F-PSMA-1007较18F-FCH升级了结果。
  • 18F-PSMA-1007检出病灶184个,18F-FCH检出63个(P=0.0006)。
  • 18F-PSMA-1007病灶分布:局部复发9%、淋巴结58%、骨33%;18F-FCH:局部复发5%、淋巴结89%、骨6%。
  • 18F-PSMA-1007高度可疑病灶占74%,18F-FCH占11%;18F-PSMA-1007高度可疑病灶SUVmax中位3.6,不确定病灶中位2.5(P<0.00001)。

临床怎么用

  • 对于根治性治疗后PSA≤2.0 ng/mL的生化复发前列腺癌患者,18F-PSMA-1007 PET/CT可能提高病灶检出率。
  • 18F-PSMA-1007可检出更多高度可疑病灶,减少不确定报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: The aim of the study was to prospectively compare performance of F-fluorocholine (FCH) and F-prostate-specific membrane antigen (PSMA)-1007 PET/CT in patients with biochemical relapse (BCR) of prostate cancer and low prostate-specific antigen levels. METHODS: We prospectively enrolled 40 BCR patients after radical treatment and prostate-specific antigen levels 2.0 ng/mL or less. F-FCH and F-PSMA-1007 PET/CT imaging was performed within a mean interval of 54 ± 21 days. Scans were done 87 ± 10 and 95 ± 12 minutes after injecting 248 ± 35 and 295 ± 14 MBq of F-FCH and F-PSMA-1007, respectively. Rates of negative, equivocal, and positive scan results were compared per patient. Per lesion, findings were grouped as equivocal or highly suggestive of malignancy and then compared for their number, localization (local relapse, lymph nodes, bones), and SUVmax values. RESULTS: Positive, equivocal, and negative results were reported in 60%, 27.5%, and 12.5% of F-PSMA-1007 and in 5%, 37.5%, and 57.5% of F-FCH scans, respectively. In 70% of scans, F-PSMA-1007 PET/CT upgraded F-FCH PET/CT results. F-PSMA-1007 scans also showed significantly more lesions (184 vs 63, P = 0.0006). Local relapse, lymph node, and bone lesions accounted, respectively, for 9%, 58%, and 33% of F-PSMA-1007 and 5%, 89%, and 6% F-FCH of PET/CT findings. Highly suspicious lesions accounted for 74% of F-PSMA-1007 and 11% of F-FCH PET/CT findings. In F-PSMA-1007 PET/CT SUVmax values of highly suggestive lesions were significantly higher than in equivocal lesions (median, 3.6 vs 2.5; P < 0.00001). CONCLUSIONS: In early BCR patients F-PSMA-1007 showed a higher detection rate than F-FCH PET/CT. The former also showed more lesions in total, more highly suggestive lesions and less equivocal lesions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Witkowska-Patena E, Giżewska A, Dziuk M, et al. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clin Nucl Med. 2019. PMID: 31689286. doi:10.1097/RLU.0000000000002794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。